Valion Bio, Inc. (NasdaqCM: VBIO)
Health Care · Biotechnology · US
$2.21
-14.67% today · -96.5% 1Y
Valion Bio, Inc. (NasdaqCM: VBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.30M and employs 52 people.
Over the last twelve months the share price has lost 96.5%, trading between 2.05 and 78.75.
Tweenvest scores Valion Bio, Inc. across four factors: quality 35/100, value 59/100. Its strongest factor is value.
VBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -210.20
- Dividend yield
- —
- Beta (5Y)
- 1.80
- 52-week high
- $78.75
- 52-week low
- $2.05
- Avg volume (3M)
- —
- Shares outstanding
- 887.59K
- Employees
- 52
- Next earnings
- —
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
- ISIN
- US8887053085
- Founded
- 2016
- Listed since
- Nov 11, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ValiRx plcAIM: VAL | $2.36M | £0.00 | +8.00% |
| International Stem Cell CorporationOTCPK: ISCO | $2.32M | $0.29 | -16.08% |
| Oncology Pharma Inc.OTCPK: ONPH | $2.32M | $0.06 | +50.00% |
| Silo Pharma, Inc.NasdaqCM: SILO | $2.32M | $1.45 | -0.55% |
| VitaSpring Biomedical Co. Ltd.OTCPK: VSBC | $2.30M | $— | — |
| Ocean Sciences LtdASX: BP8 | $2.29M | AU$0.01 | +7.69% |
| Genprex, Inc.NasdaqCM: GNPX | $2.25M | $3.00 | +8.91% |
| Lakewood-Amedex Biotherapeutics, Inc.NasdaqCM: LABT | $2.21M | $0.82 | -12.07% |
Figures last refreshed Oct 4, 2026.